Other substances

Deforolimus

mTOR inhibitor, angiogenesis inhibitor and immunosuppressant.

Phase of research

Potential treatment - theoretical effect

How it helps

Other treatment

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Ridaforolimus (Deforolimus) is an analogue of the macrolide antibiotic rapamycin with potential antitumor activity. It inhibits mammalian target of rapamycin (mTOR) (NCIt).

Deforolimus on DrugBank
Deforolimus on PubChem
Deforolimus on Wikipedia

Synonyms

Ridaforolimus

 

Structure image - Deforolimus

C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OP(=O)(C)C)C)/C)O)OC)C)C)/C)OC

Supporting references

Link Tested on Impact factor Notes Publication date
Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels
in silico 4.86

In silico screening of potential ACE2 agonists. Theoretical amelioration of ACE2 depletion by virus attachment.

 Jun/27/2020
Export (.csv)